[Animal models of osteoporosis and development of anti-osteoporotic agents].
Azuma
Yoshiaki
Y
yo.azuma@teijin.co.jp
D000818:Animals; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D009281:Naphthalenes; D009919:Orchiectomy; D010024:Osteoporosis / Q000188:drug therapy; D053244:Osteoprotegerin; D010052:Ovariectomy; D053245:RANK Ligand
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; C436740:N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine; D009281:Naphthalenes; D053244:Osteoprotegerin; D053245:RANK Ligand; D000069448:Denosumab